Nxera Pharma SG&A Expense (Quarterly) Insights

Nxera Pharma Co Ltd (SOLTF)

9.55 +0.25 (+2.65%) USD | OTCM | May 03, 16:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.

Date	Value
December 31, 2023	26.77M
September 30, 2023	23.82M
June 30, 2023	10.65M
March 31, 2023	8.396M
December 31, 2022	8.561M
September 30, 2022	6.551M
June 30, 2022	7.031M
March 31, 2022	11.66M
December 31, 2021	9.254M
September 30, 2021	8.667M
June 30, 2021	8.761M
March 31, 2021	9.206M
December 31, 2020	9.192M
September 30, 2020	7.670M
June 30, 2020	8.159M
March 31, 2020	7.190M
December 31, 2019	8.874M
September 30, 2019	6.890M
June 30, 2019	9.726M
March 31, 2019	7.637M
December 31, 2018	10.77M
September 30, 2018	6.002M

Date	Value
June 30, 2018	7.527M
March 31, 2018	11.71M
December 31, 2017	10.05M
September 30, 2017	9.494M
June 30, 2017	9.216M
March 31, 2017	7.203M
December 31, 2016	6.268M
September 30, 2016	7.972M
June 30, 2016	11.59M
March 31, 2016	9.226M
December 31, 2015	6.504M
September 30, 2015	5.656M
June 30, 2015	6.166M
March 31, 2015	11.27M
December 31, 2014	1.766M
September 30, 2014	2.328M
June 30, 2014	2.183M
March 31, 2014	2.943M
December 31, 2013	1.717M
September 30, 2013	2.209M
June 30, 2013	1.909M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

6.551M

Minimum

Sep 2022

26.77M

Maximum

Dec 2023

10.37M

Average

8.761M

Median

Jun 2021

SG&A Expense (Quarterly) Benchmarks